


## Empagliflozin

## Chemical Properties

CAS No. :	864070-44-0
Formula:	C <sub>23</sub> H <sub>27</sub> ClO <sub>7</sub>
Molecular Weight:	450.91
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Empagliflozin (BI 10773) is an SGLT-2 inhibitor (IC <sub>50</sub> =3.1 nM) that is potent and selective, with more than 300-fold selectivity for SGLT-1/4/5/6. Empagliflozin is used for the treatment of type 2 diabetes.
Targets(IC <sub>50</sub> )	SGLT
In vitro	In kinetic binding experiments, [3H]-Empagliflozin exhibited high affinity for SGLT-2 in the absence of glucose, demonstrating an average K <sub>d</sub> of 57 nM and a half-life of binding to SGLT-2 of 59 minutes. Empagliflozin competitively binds to SGLT-2 against glucose. The selectivity of Empagliflozin for hSGLT-2 was substantially higher compared to other glucose transporters: 2500 times greater than hSGLT-1 (IC <sub>50</sub> 8300 nM), over 3500 times that of hSGLT-4, more than 350 times that of hSGLT-5 (IC <sub>50</sub> = 1100 nM), and over 600 times that of hSGLT-6. Additionally, at a concentration of 10 μM, Empagliflozin did not inhibit GLUT1.
In vivo	Long-term treatment with Empagliflozin can improve blood glucose control and characteristics of metabolic syndrome in diabetic rats. After treating dogs with 5 mg/kg Empagliflozin for 24 hours, plasma concentrations were over 100 times higher than the measured IC <sub>50</sub> value. The total plasma clearance rate for Empagliflozin in ZDF rats was 43 mL/min/kg, compared to 1.8 mL/min/kg in dogs. The C <sub>max</sub> for ZDF rats and dogs treated with Empagliflozin were respectively 167 nM and 17254 nM. Additionally, the bioavailability of Empagliflozin in ZDF rats was 33.2%, whereas it reached up to 89.0% in dogs.
Kinase Assay	[14C]-monosaccharide uptake inhibition experiments: Stable cell lines over-expressing hSGLT-1, -2, -4, -5 or -6 or rSGLT-1 or -2 are used for the sodium-dependent monosaccharide transport inhibition assay. Cells are pre-incubated in 200 μL uptake buffer (10 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 2.8 mM CaCl <sub>2</sub> , 1.2 mM MgCl <sub>2</sub> , 50 μg/ml Gentamycin, 0.1% BSA) for 25 minutes at 37°C. 10 μM Cytochalasin B and test compound is added at different concentrations 15 minutes before the initiation of the uptake experiment. The uptake reaction is started by the addition of 0.6 μCi [14C]-labelled monosaccharide i.e. [14C]-labelled AMG, glucose, fructose, mannose or myo-inositol, in 0.1 mM AMG (or the respective non-radioactive monosaccharide). After incubation for 60 minutes (hSGLT-5), 90 minutes (hSGLT-4) or 4 hours (hSGLT-2) at 37°C, the cells are washed three times with 300 μL PBS and then lysed in 0.1 N NaOH with intermittent shaking for 5 minutes. The lysate is mixed with 200 μL MicroScint 40 and shaken for 15 minutes and counted for radioactivity in the TopCount NXT. For SGLT-4 and SGLT-5

## A DRUG SCREENING EXPERT

Kinase Assay	assays cells are pre-incubated in pre-treatment buffer (uptake buffer containing choline chloride instead of NaCl) for 25 minutes prior to addition of uptake buffer.
Cell Research	MTS assay(Only for Reference)

### Solubility Information

Solubility	DMSO: 242.5 mg/mL (537.8 mM),Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.3 mg/mL (18.41 mM),Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2177 mL	11.0887 mL	22.1774 mL
5 mM	0.4435 mL	2.2177 mL	4.4355 mL
10 mM	0.2218 mL	1.1089 mL	2.2177 mL
50 mM	0.0444 mL	0.2218 mL	0.4435 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Mihaljević V, et al. Molecular Mechanisms Linking Empagliflozin to Renal Protection in the LLC-PK1 Model of Diabetic Nephropathy. *Biomedicines*. 2022 Nov 20;10(11):2983.
- Tian G, Yu Y, Deng H, et al. Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway. *Clinical and Experimental Pharmacology and Physiology*. 2021, 48(6): 837-845.
- Lee WC, et al. Empagliflozin Protects HK-2 Cells from High Glucose-Mediated Injuries via a Mitochondrial Mechanism. *Cells*. 2019 Sep 14;8(9):1085.
- Kim P, Kim G Y, Cho M Y, et al. Manufacture and Characterization of Two Distinct Quasi-polymorphs of Empagliflozin. *Journal of Crystal Growth*. 2020: 125489
- Ni X, Feng X, Wang Z, et al. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. *Acta Pharmacologica Sinica*. 2024: 1-14.
- Li C, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. *Cardiovasc Diabetol*. 2019 Feb 2;18(1):15.
- Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic  $\beta$ -Cell Mass and Glucose Homeostasis in Type 1 Diabetes. *PLoS One*. 2016 Jan 25;11(1):e0147391.
- Wen Q, Zhang R, Ye K, et al. Empagliflozin rescues pro-arrhythmic and Ca<sup>2+</sup> homeostatic effects of transverse aortic constriction in intact murine hearts. *Scientific Reports*. 2024, 14(1): 15683.
- Yang K, Liang W, Hu H, et al. ESRRB modulation by empagliflozin mitigates diabetic tubular injury via mitochondrial restoration. *Cellular Signalling*. 2024: 111308.
- Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. *Int J Med Sci*. 2018 Jun 13;15(9):937-943.
- Kim P, Kim G Y, Cho M Y, et al. Manufacture and Characterization of Two Distinct Quasi-polymorphs of Empagliflozin[J]. *Journal of Crystal Growth*. 2020: 125489.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 34 Washington Street, Wellesley Hills, MA 02481